IDEATE IPILIMUMAB DRUG EVALUATION Trademark

Trademark Overview

On Tuesday, July 15, 2014, a trademark application was filed for IDEATE IPILIMUMAB DRUG EVALUATION with the United States Patent and Trademark Office. The USPTO has given the IDEATE IPILIMUMAB DRUG EVALUATION trademark a serial number of 86337421. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 11, 2022. This trademark is owned by Bristol-Myers Squibb Company. The IDEATE IPILIMUMAB DRUG EVALUATION trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Providing medical and scientific research information in the field of pharmaceuticals and clinical trials
ideate ipilimumab drug evaluation

General Information

Serial Number86337421
Word MarkIDEATE IPILIMUMAB DRUG EVALUATION
Filing DateTuesday, July 15, 2014
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 11, 2022
Registration Number4802230
Registration DateTuesday, September 1, 2015
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 16, 2015

Trademark Statements

Disclaimer with Predetermined Text"IPILIMUMAB DRUG EVALUATION"
Goods and ServicesProviding medical and scientific research information in the field of pharmaceuticals and clinical trials

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 11, 2022
Primary Code042
First Use Anywhere DateFriday, May 31, 2013
First Use In Commerce DateFriday, May 31, 2013

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10154
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10154

Trademark Events

Event DateEvent Description
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, March 11, 2022CANCELLED SEC. 8 (6-YR)
Tuesday, September 1, 2020COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Monday, October 8, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, October 8, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, August 21, 2018APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 21, 2018TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, September 1, 2015REGISTERED-PRINCIPAL REGISTER
Tuesday, June 16, 2015OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 16, 2015PUBLISHED FOR OPPOSITION
Wednesday, May 27, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, May 13, 2015LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, May 13, 2015ASSIGNED TO LIE
Tuesday, April 21, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 20, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, April 19, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, April 19, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, October 21, 2014NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, October 21, 2014NON-FINAL ACTION E-MAILED
Tuesday, October 21, 2014NON-FINAL ACTION WRITTEN
Wednesday, October 15, 2014ASSIGNED TO EXAMINER
Monday, July 21, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 18, 2014NEW APPLICATION ENTERED

Related Keywords

evaluation drug ipilimumab ideate pharmaceuticals clinical trials field information medical scientific research providing